Yahoo! FinanceHome - Yahoo! - Help

Market Guide

[ Stock Screener | Company & Fund Index | Financial Glossary ]

Profile - Vion Pharmaceuticals,Inc. (NasdaqNM:VION)
As of 31-Aug-2001
Enter symbol:
symbol lookup

 
More Info: Quote | Chart | News | Profile | Research | SEC | Msgs | Insider | Options | Financials | Reports
Location
4 Science Park
New Haven, CT 06511
Phone: (203) 498-4210
Fax: (203) 498-4211
Email: cswearngan@burnsmc.com
Employees (last reported count): 54
Financial Links
 ·Top Institutional Holders
 ·Top Mutual Fund Holders
 ·Historical Quote Data
 ·Free Annual Report
 ·Raw SEC Filings at sec.gov
Competitors:
 ·Sector: Healthcare
 ·Industry: Biotechnology & Drugs
Company Website
 ·Home Page

 ·Search Yahoo! for related links...

Ownership
·Insider and 5%+ Owners: 18%
·Institutional: 21% (25% of float)
(52 institutions)
·Net Inst. Buying: 226.0K shares (+4.00%)
(prior quarter to latest quarter)
More From Market Guide
 ·Highlights
 ·Performance
 ·Ratio Comparisons
Business Summary
Vion Pharmaceuticals, Inc. is a biopharmaceutical company engaged in research, development and commercialization of therapeutics and technologies for the treatment of cancer. The Company's product portfolio consists of one drug delivery platform and two distinct small-molecule anticancer agents. TAPET (Tumor Amplified Protein Expression Therapy), the Company's drug delivery system using live bioengineered, genetically altered Salmonella bacteria, is designed to deliver cancer-fighting drugs preferentially to solid tumors. Triapine prevents the replication of tumor cells by blocking a critical step in the synthesis of DNA. Sulfonyl Hydrazine Prodrugs are potent alkylating agents that are being evaluated in preclinical studies. The Company is developing several products for the treatment of cancer. The core product candidates are in various development statuses.
More from Market Guide: Expanded Business Description

Financial Summary
Vion Pharmaceuticals, Inc. is a biopharmaceutical company principally devoted to the research and development of therapeutic products for the treatment of cancer and cancer-related disorders. For the six months ended 6/30/01, total revenues fell 22% to $325 thousand. Net loss applicable to Common rose 7% to $7 million. Results reflect lower contract research grants received and the absence of support services fees, partially offset by higher interest income.
More from Market Guide: Significant Developments

Officers[Insider Trade Data]
FY1999 Compensation
PayExer

William Miller, 71
Chairman
--  --  
Alan Kessman, 53
Pres, CEO
$545K--  
Steven Koehler
CFO
--  --  
Thomas Mizelle, 48
VP--Operations and Sec.
232K$63K
Bijan Almassian, Ph.D., 46
VP, Devel.
192K--  
Dollar amounts are as of 31-Dec-1999 and compensation values are for the fiscal year ending on that date; "Pay" is salary, bonuses, etc.; "Exer" is the value of options excercised during the fiscal year.
More from Market Guide on Officers & Directors:
Expanded List, Bios, Compensation, Options
Statistics at a Glance -- NasdaqNM:VIONAs of 31-Aug-2001
Price and Volume
52-Week Low
on 20-Mar-2001
$2.75 
Recent Price$5.00 
52-Week High
on 2-Oct-2000
$18.75 
Beta1.22 
Daily Volume (3-month avg)103.0K
Daily Volume (10-day avg)74.0K
Stock Performance
[one-year price graph]
big chart [1d | 5d | 3m | 6m | 1y | 2y | 5y | max]
52-Week Change-71.4%
52-Week Change
relative to S&P500
-61.7%
Share-Related Items
Market Capitalization$131.7M
Shares Outstanding26.3M
Float21.6M
Dividends & Splits
Annual Dividendnone 
Last Splitnone 
Per-Share Data
Book Value (mrq)$0.61 
Earnings (ttm)-$0.61 
Earnings (mrq)-$0.12 
Sales (ttm)$0.03 
Cash (mrq)$0.67 
Valuation Ratios
Price/Book (mrq)8.23 
Price/EarningsN/A 
Price/Sales (ttm)152.34 
Income Statements
Sales (ttm)$856.0K
EBITDA (ttm)-$17.0M
Income available to common (ttm)-$15.9M
Profitability
Profit MarginN/A 
Operating MarginN/A 
Fiscal Year
Fiscal Year EndsDec 31
Most recent quarter30-June-2001
Management Effectiveness
Return on Assets (ttm)-64.04%
Return on Equity (ttm)-70.18%
Financial Strength
Current Ratio (mrq)6.45 
Debt/Equity (mrq)0 
Total Cash (mrq)$17.5M
Short Interest
As of 8-Aug-2001
Shares Short306.0K
Percent of Float1.4%
Shares Short
(Prior Month)
476.0K
Short Ratio2.81 
Daily Volume109.0K
See Profile Help for a description of each item above;   K = thousands;   M = millions;   mrq = most-recent quarter;   ttm = trailing twelve months;   (as of 30-June-2001)

Market Guide offers more in-depth Company Research, Stock Screening, and Hottest Stocks and Industries on over 10,000 U.S. Equities.


Copyright © 2001 Yahoo! Inc. All Rights Reserved. Privacy Policy - Terms of Service
Company information Copyright Market Guide. Historical chart data and daily updates provided by Commodity Systems, Inc. (CSI). Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither Yahoo nor any of its data or content providers (such as Market Guide, CSI, etc.) shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon.